OBJECTIVE: The aim of this study was to compare the survival outcomes of adenosquamous carcinoma (ASC) and adenocarcinoma (AC) of the cervix. METHODS: We searched PubMed and Embase for observational studies that compared the outcomes of 2 histologic subtypes. Hazards ratios (HRs) with 95% confidence intervals (CIs) were calculated with a fixed effects model. RESULTS: A total of 17 studies were included in the analyses. Patients with ASC were associated significantly with poorer overall survival (death HR, 1.27; 95% CI, 1.12-1.43; I(2) = 0%) and recurrence-free survival (recurrence HR, 1.43; 95% CI, 1.05-1.95; I(2) = 19.4%) than those with AC. For clinical stages I and II in particular, ASC predicted significantly poorer outcomes compared with AC (death HR, 1.41; 95% CI, 1.17-1.70; I(2) = 0%). CONCLUSIONS: This meta-analysis suggests that ASC may have poorer outcomes compared with AC of the cervix.
OBJECTIVE: The aim of this study was to compare the survival outcomes of adenosquamous carcinoma (ASC) and adenocarcinoma (AC) of the cervix. METHODS: We searched PubMed and Embase for observational studies that compared the outcomes of 2 histologic subtypes. Hazards ratios (HRs) with 95% confidence intervals (CIs) were calculated with a fixed effects model. RESULTS: A total of 17 studies were included in the analyses. Patients with ASC were associated significantly with poorer overall survival (death HR, 1.27; 95% CI, 1.12-1.43; I(2) = 0%) and recurrence-free survival (recurrence HR, 1.43; 95% CI, 1.05-1.95; I(2) = 19.4%) than those with AC. For clinical stages I and II in particular, ASC predicted significantly poorer outcomes compared with AC (death HR, 1.41; 95% CI, 1.17-1.70; I(2) = 0%). CONCLUSIONS: This meta-analysis suggests that ASC may have poorer outcomes compared with AC of the cervix.
Authors: Vivian M Spaans; Marjolijn D Trietsch; Alexander A W Peters; Michelle Osse; Natalja Ter Haar; Gert J Fleuren; Ekaterina S Jordanova Journal: PLoS One Date: 2015-07-21 Impact factor: 3.240